Helix BioPharma Corp. (HBP) - Total Assets
Based on the latest financial reports, Helix BioPharma Corp. (HBP) holds total assets worth CA$19.07 Million CAD (≈ $13.79 Million USD) as of October 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See what is Helix BioPharma Corp.'s book value for net asset value and shareholders' equity analysis.
Helix BioPharma Corp. - Total Assets Trend (2007–2025)
This chart illustrates how Helix BioPharma Corp.'s total assets have evolved over time, based on quarterly financial data.
Helix BioPharma Corp. - Asset Composition Analysis
Current Asset Composition (July 2025)
Helix BioPharma Corp.'s total assets of CA$19.07 Million consist of 2.2% current assets and 97.8% non-current assets.
| Asset Category | Amount (CAD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 0.4% |
| Accounts Receivable | CA$121.00K | 0.6% |
| Inventory | CA$0.00 | 0.0% |
| Property, Plant & Equipment | CA$4.00K | 0.0% |
| Intangible Assets | CA$18.39 Million | 97.8% |
| Goodwill | CA$0.00 | 0.0% |
Asset Composition Trend (2007–2025)
This chart illustrates how Helix BioPharma Corp.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Helix BioPharma Corp. market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Helix BioPharma Corp.'s current assets represent 2.2% of total assets in 2025, a decrease from 91.1% in 2007.
- Cash Position: Cash and equivalents constituted 0.4% of total assets in 2025, down from 79.7% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 97.0% of total assets, an increase from 0.0% in 2007.
- Asset Diversification: The largest asset category is intangible assets at 97.8% of total assets.
Helix BioPharma Corp. Competitors by Total Assets
Key competitors of Helix BioPharma Corp. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Helix BioPharma Corp. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.23 | 0.23 | 3.95 |
| Quick Ratio | 0.23 | 0.23 | 3.95 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CA$-2.33 Million | CA$-1.37 Million | CA$3.64 Million |
Helix BioPharma Corp. - Advanced Valuation Insights
This section examines the relationship between Helix BioPharma Corp.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.79 |
| Latest Market Cap to Assets Ratio | 6.20 |
| Asset Growth Rate (YoY) | 1162.7% |
| Total Assets | CA$18.80 Million |
| Market Capitalization | $116.58 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Helix BioPharma Corp.'s assets at a significant premium (6.20x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Helix BioPharma Corp.'s assets grew by 1162.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Helix BioPharma Corp. (2007–2025)
The table below shows the annual total assets of Helix BioPharma Corp. from 2007 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-07-31 | CA$18.80 Million ≈ $13.60 Million |
+1162.73% |
| 2024-07-31 | CA$1.49 Million ≈ $1.08 Million |
+44.70% |
| 2023-07-31 | CA$1.03 Million ≈ $744.36K |
-72.41% |
| 2022-07-31 | CA$3.73 Million ≈ $2.70 Million |
-8.24% |
| 2021-07-31 | CA$4.07 Million ≈ $2.94 Million |
-17.14% |
| 2020-07-31 | CA$4.91 Million ≈ $3.55 Million |
+421.91% |
| 2019-07-31 | CA$940.00K ≈ $679.98K |
-18.05% |
| 2018-07-31 | CA$1.15 Million ≈ $829.72K |
-47.55% |
| 2017-07-31 | CA$2.19 Million ≈ $1.58 Million |
-51.05% |
| 2016-07-31 | CA$4.47 Million ≈ $3.23 Million |
-42.69% |
| 2015-07-31 | CA$7.80 Million ≈ $5.64 Million |
-0.73% |
| 2014-07-31 | CA$7.85 Million ≈ $5.68 Million |
+33.83% |
| 2013-07-31 | CA$5.87 Million ≈ $4.24 Million |
-22.95% |
| 2012-07-31 | CA$7.62 Million ≈ $5.51 Million |
-68.75% |
| 2011-07-31 | CA$24.37 Million ≈ $17.63 Million |
+34.54% |
| 2010-07-31 | CA$18.11 Million ≈ $13.10 Million |
-6.24% |
| 2009-07-31 | CA$19.32 Million ≈ $13.98 Million |
-10.83% |
| 2008-07-31 | CA$21.67 Million ≈ $15.67 Million |
+51.80% |
| 2007-07-31 | CA$14.27 Million ≈ $10.32 Million |
-- |
About Helix BioPharma Corp.
Helix BioPharma Corp. a clinical-stage biopharmaceutical company developing therapies in the field of immune-oncology in Canada. Its product pipeline comprises L-DOS47, a clinical-stage antibody-enzyme conjugate (AEC) that neutralizes the microenvironment of solid tumors; LDOS001, which is in phase I clinical trial to treat non-small cell lung cancer; LDOS002, which is in phase I/II clinical tria… Read more